If you pin testosterone and your HDL drops from 45 to 35, that is expected pharmacology. Add Trenbolone and your HDL drops to 9, that is a different category of risk. Understanding the lipid impact spectrum across compounds is not academic curiosity, it is the difference between a cycle that manages risk and one that accumulates it silently.
Every AAS suppresses HDL, and they often elevate LDL and ApoB as well. That's the universal pattern. What varies enormously is the magnitude. Some compounds produce barely measurable changes at typical doses. Others produce lipid profiles that would alarm any cardiologist. Here's the full compound-by-compound breakdown, ranked by lipid impact from mildest to most severe.
Before we get to individual compounds, here's the complete picture. The table below ranks every major AAS by its effect on HDL, LDL, and ApoB, drawing on published literature and the pattern coaches in this space consistently observe.
AAS Lipid Impact Spectrum (ranked mildest to worst)
| Marker | Compound | HDL Suppression |
|---|---|---|
| Testosterone (TRT: 100-200 mg/wk) | -5 to -15% | Minimal LDL change |
| Primobolan (< 400 mg/wk) | -10 to -20% | Minimal LDL change |
| Testosterone (Blast: 300-600 mg/wk) | -20 to -40% | Mild LDL elevation |
| Nandrolone (300-600 mg/wk) | -20 to -35% | Moderate ApoB elevation |
| Boldenone / EQ (400-800 mg/wk) | -30 to -50% | Significant ApoB elevation |
| Oxandrolone / Anavar (20-50 mg/day) | -25 to -50% | Moderate LDL elevation |
| Turinabol (20-50 mg/day) | -30 to -50% | Moderate LDL elevation |
| Trenbolone (200-500 mg/wk) | -60 to -90% | Severe ApoB elevation |
| Oxymetholone / Anadrol (50-150 mg/day) | -70 to -90% | Severe HDL drop + liver stress |
| Stanozolol / Winstrol (25-50 mg/day) | -70 to -90% | Most lipid-toxic per mg |
| Superdrol (10-30 mg/day) | -80 to -95% | Extreme across all markers |
| Fluoxymesterone / Halotestin (10-40 mg/day) | -80 to -95% | Rapid, severe suppression |
These ranges represent typical responses, though individual variation exists. Some users tolerate certain compounds better than others, but the ranking order is consistent across the published literature. The compounds at the bottom of this table produce lipid values that are not just "elevated" or "suppressed" but qualitatively different from what is seen with moderate-dose testosterone alone.
When keeping your lipids in check is the main goal, these compounds come out on top. At typical doses, their effect on HDL, LDL, and ApoB stays modest, and once you stop, things bounce back quickly.
Testosterone: The Baseline
Primobolan (Methenolone) is frequently cited as the mildest compound on lipids, and the data supports this: at doses below 400 mg per week. Users report HDL drops of 10-20 percent, and LDL changes are minimal. The catch is that Primobolan is also relatively mild in anabolic effect, so users often stack it with other compounds, which complicates the lipid picture. As a standalone compound, however, it is the closest thing to a "lipid-neutral" AAS.
Nandrolone (Deca-Durabolin) occupies a middle position that is worth understanding. Its impact on HDL is moderate: typically 20-35 percent suppression at 300-600 mg per week. But nandrolone has a unique lipid signature: it tends to raise ApoB more than its HDL suppression would suggest, with ApoB elevation often disproportionate to the HDL drop. This means that if you use nandrolone, you absolutely need to measure ApoB, not just HDL and LDL. Many users assume "moderate HDL suppression = moderate overall impact," but with nandrolone, the ApoB story tells a different picture.
ApoB (Apolipoprotein B)
These compounds will move your lipid panel, and that deserves attention. But with the right lifestyle habits and smart compound selection, you can keep those changes in check without much drama.
Boldenone (Equipoise, EQ) presents a specific challenge: it causes significant HDL suppression (30-50 percent) while also elevating hematocrit more than most other injectables. The combination of suppressed HDL and elevated hematocrit creates a cardiovascular risk profile that requires active management. EQ users should monitor both markers simultaneously and be prepared to intervene if HDL drops below 20 mg/dL or hematocrit exceeds 54 percent.
💡Among moderate-impact compounds, Boldenone stands out for its dual effect on lipids and hematocrit — the combination that makes it worth monitoring more closely than its HDL numbers alone would suggest.
— The Core Pattern
Oxandrolone (Anavar) is often perceived as "mild" because it is well-tolerated in other respects. Lipids tell a different story. At 20-50 mg per day, Anavar reduces HDL by 25-50 percent: comparable to much more androgenic compounds. The reason Anavar gets a "moderate" rather than "severe" rating is that its impact on LDL and ApoB is less dramatic than the worst offenders, and recovery is relatively fast (4-6 weeks). However, a 50 percent HDL reduction is not mild by any reasonable standard. Users who run Anavar for extended periods (8+ weeks) should expect HDL in the 20-30 mg/dL range.
With a shorter half-life, Turinabol offers more flexible dosing that can reduce cumulative lipid exposure, and its lipid profile looks a lot like Anavar's: moderate-to-significant HDL suppression with manageable LDL changes. The clinical literature on Turinabol is thinner than on Anavar, but user data points to a comparable lipid impact at equivalent doses.
These compounds produce lipid values that enter pathological territory, with HDL below 15 mg/dL common and HDL below 10 mg/dL documented. At these levels, the distinction between "expected pharmacology" and "genuine risk" blurs. Few interventions can restore HDL from single digits while the compound remains on board.
The Lipid-Toxic Tier
Trenbolone is the most studied of the severe-impact compounds, and the data is consistent: HDL drops of 60-90 percent are typical. Users on 200-500 mg of Trenbolone per week frequently report HDL values between 8 and 15 mg/dL: levels that would normally warrant pharmacological intervention in a non-AAS context. ApoB elevation is equally severe, with values well above 130 mg/dL commonly reported in Trenbolone users — a level associated with meaningfully elevated cardiovascular risk in the general population.
Oxymetholone (Anadrol) combines severe HDL suppression (70-90 percent) with significant liver enzyme elevation due to its 17-alpha-alkylated structure. Anadrol's lipid impact is compounded by its tendency to elevate blood pressure and hematocrit, creating a triple threat: lipid suppression, volume expansion, and hepatic stress. Users who add Anadrol to a cycle see HDL values that are typically 30-50 percent lower than on the base testosterone dose alone, within the first two weeks of use.
Stanozolol (Winstrol) may be the most lipid-toxic compound per milligram. At just 25-50 mg per day, it produces HDL suppression comparable to 500 mg of Trenbolone. The oral route and 17-alpha-alkylated structure mean first-pass hepatic effects compound the lipid impact. Winstrol is unique in that even short cycles (4 weeks) produce significant and measurable HDL reduction.
Superdrol (Methasterone) and Halotestin (Fluoxymesterone) represent the extreme end of the spectrum. Both produce HDL suppression above 80 percent at typical doses. Halotestin is particularly notable for the speed of its effect: HDL drops measurably within days of first administration. Clinical data on these compounds is limited due to their absence from approved medical use, but user-reported values consistently place them at the top of the lipid-toxicity ranking.
Why Severe HDL Suppression Matters
Two patterns are worth understanding when compounds are stacked rather than run alone. First, the base dose of testosterone matters less than whatever else is added to it. A user on 200 mg testosterone plus 300 mg Trenbolone will have worse lipids than a user on 600 mg testosterone alone — the add-on compound is the dominant driver of lipid impact, not the testosterone dose underneath it. Second, individual variability is substantial. Some users tolerate even severe compounds reasonably well, while others experience dramatic changes at moderate doses, which is exactly why a personal baseline and follow-up testing matter more than any published range.
The ApoB/ApoA1 Ratio: Why It Matters More Than LDL
If you only track one advanced lipid marker, make it the ApoB/ApoA1 ratio. It captures the balance between atherogenic particles, ApoB, which every VLDL, IDL, LDL, and Lp(a) particle carries, and anti-atherogenic particles, ApoA1, the primary structural protein of HDL. A growing body of evidence suggests this ratio outperforms LDL cholesterol, non-HDL cholesterol, and even ApoB alone when it comes to predicting cardiovascular risk.
The INTERHEART study, a landmark case-control study published in The Lancet that included nearly 30,000 participants across 52 countries, found the ApoB/ApoA1 ratio to be the single strongest lipid-related predictor of heart attack risk. It outperformed LDL, total cholesterol, and the total/HDL ratio that many clinicians still rely on. Among AAS users, this ratio matters even more because AAS distort both sides of the equation simultaneously: they push ApoB up while pulling ApoA1 down, creating a double hit that a standard lipid panel captures poorly.
To interpret the ratio and understand its meaning in the context of AAS use, here's what you need to know.
ApoB/ApoA1 Ratio Interpretation
| Marker | Risk Category | Ratio Range |
|---|---|---|
| Optimal (non-AAS) | < 0.6 | Low cardiovascular risk; excellent particle balance |
| Optimal (on AAS) | < 0.8 | Achievable with mild compounds at moderate doses |
| Borderline elevated | 0.8 – 1.2 | Common with moderate compounds or higher doses |
| High risk | 1.2 – 2.0 | Typical with Trenbolone, Anadrol, Winstrol |
| Severe risk | > 2.0 | Seen with stacked severe compounds; warrants intervention |
The clinical relevance is straightforward. A user on 300 mg of Trenbolone per week might have total cholesterol of 180 mg/dL, a value that looks fine on a standard lipid panel, but an ApoB of 160 mg/dL and an ApoA1 of 80 mg/dL, yielding a ratio of 2.0. That same user's licensed medical professional, looking only at the standard panel, would see nothing alarming. The ApoB/ApoA1 ratio reveals risk that would otherwise go undetected.
ApoA1
Why the Ratio Matters More on AAS
When you pull the compound, how long before your lipids bounce back? That depends on how hard they were suppressed, which compound you're running, and your own individual response. The evidence points to a few clear patterns.
Recovery Is Proportional to Severity
ApoB elevation often outlasts HDL suppression by a wide margin. A user might see HDL return to 35 mg/dL within 6 weeks of stopping Trenbolone, but ApoB can remain elevated at 120+ mg/dL for 12 weeks or more. That timing gap makes "lipid recovery" based on a standard panel misleading, since those panels do not include ApoB. If you measure only HDL and LDL, you might conclude your lipids have normalized while your atherogenic particle count is still elevated.
Recovery also hinges on how much cumulative damage you've stacked up from past cycles. A first-time user of a severe compound usually bounces back fully within 12-16 weeks. But if you've run Trenbolone three times in two years, your HDL might settle at 28-32 mg/dL instead of returning to your pre-AAS baseline of 45-50 mg/dL. Most of the literature on discontinued AAS use finds cholesterol values normalizing within about 6 months for the average user, but that average hides real variation — long-term, heavy users are the ones most likely to see HDL stay suppressed well beyond that window. That points to a threshold effect: past a certain cumulative exposure, lipid changes can become harder to fully reverse.
ApoB Recovery Lag
Practical recovery protocol: Test lipids (full panel including ApoB and ApoA1) at 4 weeks post-cycle, then again at 12 weeks post-cycle. If HDL has returned to within 10% of baseline by week 12, recovery is on track. If ApoB remains above 110 mg/dL at week 12 despite HDL normalization, extend monitoring to week 16 and consider adding ApoB-lowering supplements (omega-3s at 3-4 g/day, bergamot polyphenols). If neither HDL nor ApoB has substantially recovered by week 12, investigate further: you may have a pre-existing lipid condition that AAS unmasked, or cumulative damage from prior cycles.
How do you pick compounds based on your starting lipid profile? The decision tree hinges on where you are before the cycle begins.
Starting HDL Above 40 mg/dL: Good Starting Point
Starting HDL Between 25-40 mg/dL: Moderate Caution
Starting HDL Below 25 mg/dL: High Caution
Beyond compound choice, there are practical steps that make a measurable difference. Cardiovascular exercise (30+ minutes daily) consistently produces 5-10 percent HDL improvements in users across all compound categories. Omega-3 supplementation at 3-4 grams of EPA+DHA per day reduces ApoB by 10-15 percent in most users. Most importantly, avoiding the combination of severe compounds, stacking Trenbolone with Winstrol for example, is not just additive but synergistic in lipid damage. The worst lipid profiles consistently come from stacks of multiple severe compounds, not from any single one.
The Real Risk Is Cumulative
Evidence-Based Lipid Support During Cycle
No supplement can fully neutralize the lipid impact of severe AAS. That's the reality you're working with. But several compounds have demonstrated measurable benefits in clinical trials and in real user data. Here is a tiered protocol, organized by the strength of the evidence and the effect size you can realistically expect.
Tier 1: High evidence, moderate effect (5-15% improvement)
Omega-3 fatty acids (EPA + DHA): This is the most well-supported intervention for AAS users. At 3-4 grams of combined EPA and DHA per day (not 3-4 grams of fish oil, but 3-4 grams of the active fatty acids), omega-3s reduce ApoB by 10-15%, lower triglycerides by 15-30%, and provide anti-inflammatory effects that partially offset the vascular impact of dyslipidemia. Meta-analyses of EPA-predominant formulations (at least 2 g/day EPA) have generally found the most consistent cardiovascular benefit among omega-3 studies. For AAS users specifically, omega-3s appear to blunt the ApoB rise even when HDL suppression continues: making them particularly valuable for preserving the ApoB/ApoA1 ratio. Choose a high-concentration ethyl ester or triglyceride-form product and split the dose AM/PM to improve absorption.
Fiber (soluble, 10-25 g/day): Psyllium husk, beta-glucan (oat fiber), and glucomannan bind bile acids in the gut, forcing the liver to use cholesterol for bile production instead of releasing it into circulation. The effect on LDL is 5-10% reduction: modest but additive with other interventions. Most AAS users consume far less fiber than optimal due to high-meat diets. Adding 10 grams of psyllium before two meals per day is a practical starting point.
Tier 2: Moderate evidence, small to moderate effect (5-10% improvement)
Bergamot polyphenolic extract: Bergamot contains unique flavonoids (brutieridin and melitidin) that act as statin-like HMG-CoA reductase inhibitors with additional antioxidant effects. Clinical studies show LDL reductions of 15-25% and HDL increases of 5-10% at 500-1000 mg/day of standardized extract. Bergamot is particularly interesting for AAS users because it appears to work through multiple pathways: inhibiting cholesterol synthesis while also improving HDL function. Small studies in metabolic syndrome patients have found bergamot extract partially improves HDL function, suggesting it might help with the HDL quality problem that AAS create, though this hasn't been studied specifically in AAS users.
CoQ10 (ubiquinol, 200-300 mg/day): Statins deplete CoQ10 because the same pathway (HMG-CoA reductase) produces both cholesterol and CoQ10. AAS may create a similar metabolic bottleneck. CoQ10 is not a lipid-lowering agent, but it supports mitochondrial function in the heart and vascular endothelium: particularly relevant when lipids are under stress. Ubiquinol (the reduced form) has better bioavailability and is preferred for athletes.
Tier 3: Limited evidence, use with caution
Red yeast rice: Contains monacolin K, which is chemically identical to lovastatin. It lowers LDL by 15-25% in most users. However, red yeast rice products vary wildly in potency (some contain virtually no active ingredient, while others contain statin levels equivalent to prescription doses). Quality control is inconsistent, and the active compound carries the same muscle and liver risks as prescription statins. If you use red yeast rice, choose a brand with third-party verification and monitor liver enzymes and creatine kinase. A better approach: discuss low-dose rosuvastatin (2.5-5 mg/day) with a licensed medical professional who understands AAS use: it is more predictable, better studied, and safer with proper monitoring.
Niacin (nicotinic acid): Niacin raises HDL more effectively than any other supplement (15-35% in clinical trials). However, its use in AAS users is complicated. Niacin also causes prostaglandin-mediated flushing (manageable with the no-flush inositol hexaniacinate form, though the lipid benefits may differ), raises blood glucose, and can elevate liver enzymes at high doses (2+ g/day). For AAS users already dealing with liver stress from oral compounds, niacin's hepatic effects are a genuine concern. If you use niacin, limit to 500-1000 mg/day of immediate-release nicotinic acid, take with food, and monitor ALT/AST and fasting glucose.
Start Before Cycle
Start your omega-3s at 3-4 g EPA+DHA per day, add soluble fiber, and throw in bergamot extract a solid 2-4 weeks before the cycle kicks off. That window gives your lipids time to settle into a baseline on those supplements, before the AAS start doing their thing to your metabolism. When that pre-cycle bloodwork comes due, pull a full lipid panel and make sure ApoB and ApoA1 are on the order sheet.
Recheck at Mid-Cycle (Week 4-6)
If your HDL has dropped more than 40% from baseline, or ApoB has climbed above 120 mg/dL, it's time to escalate. Start by adding CoQ10 at 200 mg/day if you're not already on it. Then take a hard look at your compound selection and ask whether it actually fits your lipid tolerance.
Post-Cycle Recovery Support
Keep all supplements running for at least 8 weeks after the cycle ends. The weeks right after you stop the compounds are when reverse cholesterol transport is most active, and your body is clearing out the lipid debris. Maintain your omega-3s and fiber during that stretch, then retest at week 12 post-cycle to confirm recovery.
Supplements Are Support, Not Salvation
Cholesterol on AAS isn't a simple 'steroids are bad for your lipids' story. It's a spectrum that ranges from barely measurable to profoundly pathological. Testosterone at moderate doses produces manageable changes, and Primobolan at reasonable doses is the mildest option available. Anavar and Turinabol are surprisingly impactful for their reputation. Then you have Trenbolone, Anadrol, Winstrol, Superdrol, and Halotestin, which form a tier of compounds that produce lipid values that enter genuinely concerning territory.
The practical implication is straightforward: if you care about cardiovascular longevity, choose your compounds with the same precision you apply to dosing, training, and diet. The evidence is clear that compound choice is the single most powerful lever for lipid management on cycle. No supplement, no lifestyle intervention, and no medication can fully compensate for choosing a severe-impact compound when a moderate one would achieve your goals.